SEC Form 4 · accession 0001214659-19-001392
Mirati Therapeutics, Inc. · MRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Faheem Hasnain
Director
Period of report
Feb 15, 2019
Accepted (ET)
Feb 20, 2019 · 5:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001576263
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (Right to Buy)F1 | $72.62 | Feb 15, 2019 | A | 47,000 | A | — | Feb 14, 2029 | Common Stock | 47,000 | 47,000 | D |
Explanation of responses
- F1The shares subject to the Option vest and become exercisable in 36 equal monthly installments following the date of grant.